LXRX News and Press, Lexicon Pharmaceuticals Inc. From 06/19/24

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexiconȁ...

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pha...

2024-06-17 07:30:04 ET H.C. Wainwright analyst issues BUY recommendation for LXRX on June 17, 2024 06:10AM ET. LXRX was trading at $1.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendat...

THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange Count...

THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon’s president and chief financial officer and Craig Granowitz, M.D., Ph.D., Lexicon ...

2024-05-28 06:47:51 ET Summary Lexicon Pharmaceuticals has a strong cash position and multiple late-stage assets. However, the company is facing low revenues and high expenses. Overall, Lexicon Pharmaceuticals' financial situation presents a mixed outlook for the company. ...

THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related ...

THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentati...

2024-05-05 05:14:07 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Conference Call May 2, 2024 05:00 PM ET Company Participants Lisa DeFrancesco - Head of Investor Relations and Strategy Lonnel Coats - Chief Executive Officer and Director Jeffrey Wade -...

2024-05-02 16:32:39 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset Lexicon Pharmaceuticals Q1 2024 Earnings Preview Lexicon stock slides 8% after rallying 30% in prior session Seeking Alpha’s ...